An op-ed by Chrissy Buteas, HINJ President and Chief Executive Officer.
May 20, 2024 – New Jersey has long been home to some of the world’s leading research-based biopharmaceutical companies. Many have made New Jersey a base for their global, North American, or U.S. operations. Aside from their contributions to human health and patients worldwide, our state’s biopharmaceutical community is responsible for 16% of New Jersey’s Gross Domestic Product, contributing $120.9 billion in total impact to our state economy annually. These economic benefits manifest in our skilled workforce and robust job opportunities, directly and through our statewide supply chain, making New Jersey a life sciences leader on the global stage. Read the full op-ed here.